PPD inks deal with China’s HLT to create data science-driven research solutions

Handshake business deal executives
Pharmaceutical Product Development inked a deal with China’s Happy Life Tech to develop data science-driven research solutions for the country’s growing drug development market. (Pixabay)

Pharmaceutical Product Development (PPD), a North Carolina-based CRO, has inked a deal with China’s Happy Life Tech (HLT) to develop data science-driven research solutions for the country’s growing drug development market.

Financial terms of the collaboration were not disclosed.

The partnership will focus on data-driven feasibility, patient recruitment and real-world evidence offerings for both global and China-based pharma and biotech companies. Combined, the two companies will offer services that are powered by HLT’s AI and data tech with PPD’s extensive expertise in clinical trial management and evidence generation. HLT boasts a network of physicians at more than 100 hospitals in 22 Chinese provinces.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“Our focus on sites with access to eligible patients is designed to speed patient recruitment at high-performing sites and to more effectively incorporate Chinese patients into global trials,” David Simmons, chairman and CEO of PPD, said in a statement. “We will help clients adapt study protocols to the China market, while helping sites enhance quality, drive performance and lead global multicenter trials.”

PPD has nearly 20 years of extensive experience in Asia-Pacific and provides a broad range of Phase I-IV services in the region. The company has clinical trial operations based in Beijing and Shanghai and central laboratory facilities in Shanghai.

Read more on

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.